{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-003041","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.725846+00:00","generated_at":"2026-06-15T13:27:54.969809+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corvus reports Q1 net loss of $7.9M; CPI-818 shows 6/13 ORR in ALC>900 TCL patients","bullets":["Net loss of $7.9M vs $8.3M in Q1 2022; cash & securities $34.5M as of March 31, 2023.","CPI-818 Phase 1/1b TCL: 2 CR, 1 nodal CR, 3 PR among 19 evaluable; 9 patients remain on therapy.","ALC>900 biomarker selected 6/13 ORR; median PFS 19.9 months for ALC>900 vs 2.1 months for <900.","CFO expects FY2023 net cash use of $19-22M; projected year-end cash of $20-23M funding into 2024.","Plans to meet with FDA in Q3 2023 to discuss potential registrational Phase 3 trial for CPI-818."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-003041","json":"https://secwatch.observer/filing/0001171843-23-003041.json","markdown":"https://secwatch.observer/filing/0001171843-23-003041.md","text":"https://secwatch.observer/filing/0001171843-23-003041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323003041/0001171843-23-003041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323003041/f8k_050823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:27:54.969809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7b83db5a062e3c17cddaa5c4deb54127be62862","claim":"Corvus Pharmaceuticals, Inc. reported the three months ended March 31, 2023 results: net income $7.9 million.","evidence_excerpt":"The net loss for the three months ended March 31, 2023 was $7.9 million compared to a net loss of $8.3 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626971/000117184323003041/0001171843-23-003041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"$7.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}